Session Details
[29-53-pm1]Clinical Pharmacy 29, Pharmacotherapies (Cancer)
Sun. Mar 29, 2026 1:10 PM - 3:10 PM JST
Sun. Mar 29, 2026 4:10 AM - 6:10 AM UTC
Sun. Mar 29, 2026 4:10 AM - 6:10 AM UTC
Room 53 (B306, Bldg. 1, Area 2 [3F])
Discusser: Fukumori Akio, Ikuko Yano
[29-53-pm1-01]A case of nutritional intake difficulty due to dysgeusia during dabrafenib plus trametinib combination therapy
○YUKI MURATOMI1 (1. Welcia Pharmacy)
[29-53-pm1-02]Evaluation of anti-tumor effect and tissue distribution of the novel photosensitizer-conjugated antibody
○Toshiyuki Goto1, Sally Danno1, Chie Ueda1, Kumi Tsutsumi1, Yosky Kataoka1 (1. Kobe university)
[29-53-pm1-03]Aging in Gut Microbiome affect the efficacy of Immune Checkpoint Inhibitors
○Junya Isobe1, Yuya Hirasawa2, Atsuo Kuramasu3, Masahiro Hosonuma2,3, Toshiaki Tsurui2,3, Hitoshi Toyoda2,3, Yuta Baba2,3, Kohei Tajima3,4, Eiji Funayama2,3, Midori Shida3, Emiko Mura2, Risako Suzuki2, Nana Iriguchi2, Tomoyuki Ishiguro2, Ryotaro Ohkuma2, Masahiro Shimokawa2, Hirotsugu Ariizumi2, Yutarao Kubota2, Satoshi Wada2,3, Takuya Tsunoda2, Atsushi Horiike2, Kiyoshi Yoshimura2,3 (1. Sch. Pharm. Sci., Showa Medical Univ., 2. Sch. Med. Sci., Showa Medical Univ., 3. Inst. Clin. Pharmacol., Showa Medical Univ., 4. Sch. Med. Sci., Tokai Univ.)
[29-53-pm1-04]Self-efficacy and awareness transformation in pharmacists' medication guidance for cancer pain: A comparative study before and after training
○Rina Sawada1, Shinji Takayama1, Akinori Oyama1, Yukino Yamazaki1, Kazumi Goto1 (1. St. Luke’s International Hospital)
[29-53-pm1-05]Risk assessment of renal dysfunction due to the combination of immune checkpoint inhibitors and cytotoxic anticancer drugs
○Hayato Namatame1, Yusuke Washino1, Yuri Saeki1, Hiroyuki Mizoguchi1, Hiroaki Ikesue1 (1. Nagoya Univ Hosp.)
[29-53-pm1-06]Physiological significances of lipid compounds related to the immunomodulatory drug's efficacy for multiple myeloma
○Muneshige Tokugawa1,3, Masaki Ri2, Yuzuha Fujii3, Wakana Furuta3, Chisato Takahashi3, Shinsuke Iida2, Keiko Maekawa3 (1. Sch. Pharm., Aichi Gakuin Univ., 2. Grad. Sch. Med. Sci., Nagoya City Univ., 3. Sch. Pharm., Doshisha Women's College of Liberal Arts)
[29-53-pm1-07]Analysis of risk factors for early discontinuation of bevacizumab in patients with hepatocellular carcinoma receiving atezolizumab and bevacizumab treatment.
○Daisuke Kanai1, Yuki Kawarada1, Mari Iinuma1, Hiroyuki Mizoguchi1, Hiroaki Ikesue1 (1. Department of Hospital Pharmacy , Nagoya University Hospital)
[29-53-pm1-08]A case of immune-related encephalitis associated with Nivolumab therapy in a patient with gastric cancer
○Akira Ota1,2, Takashi Sekikawa3, Hideki Sugita 1,2, Shoko Nakamura1,2, Yoshiaki Mihara3, Takehiro Takahashi3, Hiroo Ishida3, Wataru Ichikawa3, Hisato Fujihara1,2 (1. Dept. of Hosp. Pharm., Sch. Pharm., Showa Med. Univ., 2. Dept. Pharm., Showa Med. Univ. Fujigaoka Hosp., 3. Div. of Med. Oncol., Dept. of Intern. Med., Showa Med. Univ. Fujigaoka Hosp.)
[29-53-pm1-09]Comprehensive analysis of genes associated with Cytarabine-induced maculopapular rash
○Hideaki Omatsu1, Kazuhiro Yamamoto2, Hiroaki Matsuo3, Mao Kurobane1, Yoshitaka Tayama1, Akiyoshi Kikkawa1, Shizuko Maeda1, Masamitsu Nakajima1, Koji Kimura1 (1. Pharm. Sci., Hiroshima International Univ., 2. Department of Integrated Clinical and Basic Pharmaceutical Sciences, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 3. Department of Pharmaceutical Services, Hiroshima University Hospital)
[29-53-pm1-10]Serum profiles of pembrolizumab, IL-6, and troponin T in a plasmapheresis-treated patient with immune checkpoint inhibitor-induced myocarditis
○Kazumasa Narita1, Sho Suzuki2, Koichiro Kuwahara2, Takafumi Naito1 (1. Dept of Pharm, Shinshu Univ Hosp, 2. Dept of Cardio. Med., Shinshu Univ Hosp)